Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;36(3):1091-1099.
doi: 10.1111/jocs.15283. Epub 2021 Jan 28.

Anticoagulation and antiplatelet therapy post coronary artery bypass surgery

Nimryta Sembi  1 , Timothy Cheng  1 , Wishvan Ravindran  1 , Edagul Ulucay  1 , Amna Ahmed  1 , Amer Harky  2   3   4
Affiliations
Review

Anticoagulation and antiplatelet therapy post coronary artery bypass surgery

Nimryta Sembi et al. J Card Surg. 2021 Mar.

Abstract

Background: Coronary artery bypass grafting (CABG) is the gold standard treatment for patients with multivessel coronary heart disease. Although its use has proven long-term survival benefits, there is a relative degree of graft failure which increases morbidity and mortality rates.

Discussion: This review discusses clinical outcomes following antiplatelet and anticoagulant therapy after CABG. There is wide variation of evidence about the use of clopidogrel or ticagrelor to aspirin postoperatively in relation to improving graft patency rates or clinical outcomes over the use of aspirin alone. These dual therapies may have significant protective effects in patients undergoing off-pump CABG. Recent studies suggest that superior outcomes may be attained by combining prasugrel with aspirin. Further research is needed to evaluate this, as well as compare the effectiveness of different dual antiplatelet regimens. There is weak evidence for post-CABG anticoagulation, with warfarin and rivaroxaban providing no protection against graft failure but decreasing long-term major adverse cardiac events. Anticoagulation seems to be indicated only in post-CABG patients at high risk of future ischemic events.

Conclusion: The use of dual anti-platelet therapy post coronary artery bypass surgery needs further research. Potentially, selective patient groups will benefit more from the addition of thienopyridine antiplatelets or anticoagulants to aspirin after CABG.

Keywords: aspirin; cardiac surgery; platelets; secondary prevention.

PubMed Disclaimer

References

REFERENCES

    1. DeStephan CM, Schneider DJ. Antiplatelet therapy for patients undergoing coronary artery bypass surgery. Kardiol Pol. 2018;76(6):945-952. https://doi.org/10.5603/KP.a2018.0111
    1. Waters David D, Azar Rabih R. Postscripts from the post coronary artery bypass graft trial. Circulation. 2000;102(2):144-146. https://doi.org/10.1161/01.CIR.102.2.144
    1. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331-344. https://doi.org/10.1038/nrg.2016.160
    1. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. https://doi.org/10.1093/eurheartj/ehy394
    1. Parmeshwar N, Fero KE, Manecke G, Coletta JM. Off-pump versus on-pump: long-term outcomes after coronary artery bypass in a veteran population. J Cardiothorac Vasc Anesth. 2019;33(5):1187-1194. https://doi.org/10.1053/j.jvca.2018.11.003

LinkOut - more resources